MME and acute lymphoblastic leukemia: In our predicate method, the ClearLLab 10C system, co-expression of CD123 with CD34 and CD19 assessment within the ClearLLab M2 panel, used to identify precursor B-cells, together with CD19, CD10 and CD34 co-expression in the ClearLLab B-cell tube, therefore offers more diagnostic information than the DURAClone ALB tube alone for the follow-up of precursor B-ALL and residual disease assessment.